Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Net Income

The latest net income for EUCRU is $5.4M as of December 2022. That compares with $6.5M in the prior-year period — down 15.8% year over year. That is below the sector sector average of $98M. Investors often review this figure alongside Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EUCRU's net income moved from $6.5M to $5.4M — a 15.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s operating scale or balance-sheet position.

Against its sector companies, EUCRU currently prints $5.4M for net income, while the sector average sits near $98M. That is roughly 94.4% below the sector mean. Large gaps often invite a closer look at Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s growth, margins, and balance sheet.

A net income figure of $5.4M for EUCRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $98M. Explore the charts below for those layers of context.

After noting EUCRU's net income ($5.4M), review year-over-year change from $6.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.